Targeting TNF-α for cancer therapy
Open Access
- 1 January 2009
- journal article
- Published by Springer Nature in Journal of Biology
- Vol. 8 (9) , 85
Abstract
As the tumor vasculature is a key element of the tumor stroma, angiogenesis is the target of many cancer therapies. Recent work published in BMC Cell Biology describes a fusion protein that combines a peptide previously shown to home in on the gastric cancer vasculature with the anti-tumor cytokine TNF-α, and assesses its potential for gastric cancer therapy.Keywords
This publication has 14 references indexed in Scilit:
- A novel peptide (GX1) homing to gastric cancer vasculature inhibits angiogenesis and cooperates with TNF alpha in anti-tumor therapyBMC Cell Biology, 2009
- Launching a Novel Preclinical Infrastructure: Comparative Oncology Trials Consortium Directed Therapeutic Targeting of TNFα to Cancer VasculaturePLOS ONE, 2009
- A review on pro- and anti-angiogenic factors as targets of clinical interventionPharmacological Research, 2006
- TUMOR STROMA AND REGULATION OF CANCER DEVELOPMENTAnnual Review of Pathology: Mechanisms of Disease, 2006
- Stromagenesis: The changing face of fibroblastic microenvironments during tumor progressionSeminars in Cancer Biology, 2005
- Characterization of a specific phage-displayed peptide binding to vasculature of human gastric cancerCancer Biology & Therapy, 2004
- Tumour necrosis factor α: a potential target for the therapy of solid tumoursThe Lancet Oncology, 2003
- A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivoProceedings of the National Academy of Sciences, 2002
- Progress in antiangiogenic gene therapy of cancer.2000
- αv Integrins as receptors for tumor targeting by circulating ligandsNature Biotechnology, 1997